CHAPTERS
- 0:00 – 1:13
Mushroom felt hats: amadou, Otzi, and portable fire
Joe and Paul open by examining Paul’s mushroom felt hat made from Fomes fomentarius (amadou). Paul explains how this fungus was used historically for carrying embers, surviving cold migrations, and later as tinder for early firearms—linking fungi to major human technological shifts.
- 1:13 – 4:02
How amadou becomes fabric: ash-water processing and felting
Paul walks through the practical process of turning a tough polypore conk into a pliable textile. They discuss alkaline ash-water soaking, delamination, pulling fibers into felt, durability, and fire risk—plus modern artisanal production in Transylvania.
- 4:02 – 4:51
Preserving a vanishing craft: Transylvanian hat makers and how to buy
They shift from technique to cultural preservation—how the number of traditional hat makers dwindled and how orders helped keep the craft alive. Paul shares where listeners can find and purchase hats to support the remaining makers.
- 4:51 – 8:57
Mushrooms and the bee ‘insect apocalypse’: antiviral discoveries and Nature paper
Paul outlines the scale of insect decline and introduces his team’s research showing mushroom mycelium extracts can drastically reduce bee viruses. He describes publishing results within the Nature ecosystem and explains the varroa mite/virus cascade harming colonies.
- 8:57 – 14:58
Citizen-science bee feeders: deployment, vertical ‘ecological ladders,’ and big-data monitoring
Paul presents a practical intervention: free bee feeders delivering mushroom extracts in sugar water, designed for widespread public participation. They discuss scaling via neighborhoods, vertical gardens, solar/wifi instrumentation, and building a global baseline dataset for pollination health.
- 14:58 – 18:02
Root causes of collapse: pesticides, monoculture ‘pollination deserts,’ and virus spread via flowers
The conversation digs into why bees and insects are disappearing: pesticides, habitat loss, factory farming, and viral pandemics spread through shared flowers. Paul explains how colony collapse can happen abruptly and why nurse-bee dynamics amplify mite/virus impacts.
- 18:02 – 22:30
Cellphone hypothesis, bee behavior stories, and research design nuances
Joe asks about cellphones as a contributing factor; Paul stays cautious and calls for stronger data. They share anecdotes about bee communication and discuss ‘bee drift’ between colonies that can dilute experimental differences—yet the results remain statistically strong.
- 22:30 – 25:11
From bee immunity to human health: translational medicine and the case for complex natural products
Paul argues the bee findings support a broader view: complex natural mixtures can provide wider ‘bioshields’ than single-target pharmaceuticals. He introduces physician-facing resources and stresses that clinical evidence for medicinal mushrooms is rapidly expanding.
- 25:11 – 27:56
Psilocybin enters mainstream science: universities, PTSD/addiction outcomes, and microdosing potential
They review the rapid legitimation of psilocybin research across major institutions and highlight notable results such as tobacco cessation. Paul expands into microdosing as a tool for creativity, cognition, and solving societal-scale problems.
- 27:56 – 30:58
microdose.me app: building baselines, cognitive tests, and finding signals in big data
Paul announces an app to standardize self-tracking for microdosing (and non-psychoactive baselines), measuring performance markers and enabling large datasets for clinicians. They discuss hypotheses like tinnitus improvement and the creativity–happiness feedback loop.
- 30:58 – 36:43
Microdosing vs macrodosing: mouse fear-conditioning study and competing protocols
Paul describes a mouse study suggesting microdosing may reduce conditioned fear faster than higher doses, connecting it to potential PTSD mechanisms and neurogenesis. He compares the Fadiman protocol with the Stamets protocol and argues for broader outcome testing beyond mood scores.
- 36:43 – 51:45
Psilocybin analogs, baeocystin self-experiment, and the ‘stack’ with lion’s mane + niacin
Paul recounts an N-of-1 bioassay of baeocystin—legal psilocybin analog—reporting reduced anxiety without intoxication. He argues the future may involve standardized natural mixtures and describes his microdosing ‘stack’ rationale, including niacin as an anti-abuse and delivery mechanism.
- 51:45 – 1:08:17
Legalization and the cultural shift: decriminalization, ‘Spore Wars,’ and Fantastic Fungi
They move to policy and culture—Oakland/Denver decriminalization models, tensions around sale vs possession, and the rise of commercial ‘economic opportunists.’ Paul promotes the documentary Fantastic Fungi as a grassroots catalyst and discusses the mainstream rebrand of psychedelics.
- 1:08:17 – 1:22:24
Safety, responsibility, and who should not take psychedelics: schizophrenia risk and set/setting
Joe raises mental health risks, especially schizophrenia vulnerability and cannabis-triggered breaks, and Paul agrees caution is warranted while deferring to clinicians. They emphasize dosage, individual variability, responsible frameworks (sitters/therapists), and the importance of structured support.
- 1:22:24 – 1:36:48
Medicinal mushrooms deep dive: lion’s mane neurogenesis, mycelium vs fruiting bodies, and microbiome effects
They pivot to non-psychedelic functional mushrooms—especially lion’s mane—covering evidence for neurite outgrowth and synergy with psilocybin analogs. Paul argues mycelium often contains more active immune-related compounds than fruiting bodies and connects fungi to soil carbon storage and human gut health.
- 1:36:48 – 1:48:54
Cordyceps complexity, product quality, and Host Defense research approach
Paul explains why Cordyceps sinensis research is taxonomically messy due to multiple fungi co-occurring, and suggests Cordyceps militaris as a cleaner choice. They discuss sourcing, labeling mycelium vs fruiting body, athletic use, and Paul’s company (Host Defense) as a research-driven operation.
- 1:48:54 – 1:59:55
Amanita warnings and the pantherina horror story: legality doesn’t mean safety
Paul shares intense experiences with Amanita muscaria and especially Amanita pantherina, emphasizing dangerous effects like repetitive motion syndrome, temporary insanity, convulsions, and hypothermia risk. The segment serves as a strong harm-reduction contrast to psilocybin’s typical profile.
- 1:59:55 – 2:06:57
Mushrooms, religion, and lasting psychological benefits: re-remembering and clinical spirituality outcomes
They discuss claims linking mushrooms to religious traditions and art, with Paul acknowledging influence while rejecting overconfident historical conclusions. He highlights Johns Hopkins findings on mystical experiences, lasting positive personality change, and the idea that recalling profound sessions may help overwrite trauma responses.
- 2:06:57 – 2:12:08
Where this is headed: therapy centers, global momentum, and closing reflections
They close by noting that guided psychedelic therapy training is already underway and that legalization trends are moving steadily forward. Paul stresses psilocybin’s anti-addictive nature, responsible use, and community-minded leadership as the movement scales.
